About LogicBio
LogicBio is a company based in Lexington (United States) founded in 2013 was acquired by Alexion in October 2022. LogicBio has raised $49 million across 3 funding rounds from investors including Alexion, Orbimed and Edmond de Rothschild. LogicBio operates in a competitive market with competitors including Spark Therapeutics, AskBio, Unity Biotechnology, Editas Medicine and GBT, among others.
- Headquarter Lexington, United States
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Logicbio Therapeutics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of LogicBio
Unlock access to complete
Leadership Team
54 people
Human Resources and Administration
25 people
Sales and Marketing
18 people
Finance and Accounting
16 people
Software Development Team
11 people
Product Management Team
10 people
Regional Team
9 people
Head Team
6 people
Unlock access to complete
Funding Insights of LogicBio
LogicBio has successfully raised a total of $49M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $20 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in LogicBio
LogicBio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Alexion, Orbimed and Edmond de Rothschild.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt firm focused on the life sciences sector
|
Locked | Locked | Locked | |
|
Structured debt is provided to life sciences and technology firms.
|
Locked | Locked | Locked | |
|
Investments in biotech startups are made by Arix Bioscience.
|
Locked | Locked | Locked |
Investor details for LogicBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by LogicBio
Investment portfolio details for LogicBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - LogicBio
Detailed financials for LogicBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Logicbio Comparisons
Peer comparison for LogicBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of LogicBio
LogicBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spark Therapeutics, AskBio, Unity Biotechnology, Editas Medicine and GBT, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| Locked | Locked | Locked |
Small molecules are developed for sickle cell disease treatment.
|
|
| Locked | Locked | Locked |
Gene therapies for rare liver and eye diseases are developed.
|
Detailed competitors of LogicBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Logicbio
Complete news archive for LogicBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LogicBio
LogicBio was founded in 2013 and raised its 1st funding round 3 years after it was founded.
LogicBio is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Frederic Chereau is the current CEO of LogicBio.
LogicBio is a funded company, having raised a total of $49M across 3 funding rounds to date.
LogicBio Therapeutics was founded in 2013 and is headquartered in Lexington, United States. Operations focus on the biotechnology sector, where gene therapy platforms based on non-pathogenic Adeno-Associated Viral (AAV) vectors are developed. These vectors target genetic conditions such as hemophilia and methylmalonic acidemia (MMA), along with infectious diseases including HIVAIDS, for use in both pediatric and adult patients.
LogicBio's top competitors include Spark Therapeutics, Generation Bio and GBT.
LogicBio has 8 investors. Key investors include Alexion, Orbimed, Edmond de Rothschild, Oxford Finance, and Horizon Tech Finance.